Nucleoside and nucleotide analogues are largely used in the treatment of cancer and viral infections.
A large number of novel compounds continue to be synthesized and evaluated both by academia and the pharmaceutical industry, which underlines the important interest in this family of drugs.
Different strategies are being used to develop new agents, such as pronucleotides and conjugates.
New agents are expected to have different resistance profiles compared to already approved agents.
New interferon-free regimens to cure hepatitis C virus infection are likely to contain a potent and pan-genotypic active nucleoside or nucleotide analogue. Two of these — sofosbuvir and mericitabine — are in Phase III clinical trials.
Nucleoside analogues have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with cancer or viral infections. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Here, we review new nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects. We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Elion, G. B. The quest for a cure. Annu. Rev. Pharmacol. Toxicol. 33, 1–23 (1993).
Elion, G. B. Acyclovir: discovery, mechanism of action, and selectivity. J. Med. Virol. Suppl. 1, 2–6 (1993).
De Clercq, E. A 40-year journey in search of selective antiviral chemotherapy. Annu. Rev. Pharmacol. Toxicol. 51, 1–24 (2011). This is a state-of-the-art review of the development of antiviral compounds, written by one of the pioneers in the field.
Holy, A. Antiviral acyclic nucleoside phosphonates structure activity studies. Antiviral Res. 71, 248–253 (2006).
De Clercq, E. & Holy, A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature Rev. Drug Discov. 4, 928–940 (2005).
Cano-Soldado, P. & Pastor-Anglada, M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med. Res. Rev. 32, 428–457 (2011).
Minuesa, G. et al. Drug uptake transporters in antiretroviral therapy. Pharmacol. Ther. 132, 268–279 (2011).
Roizman, B. & Knipe, D. M. in Fundamental Virology (eds Knipe, D. M. & Howley, P. M.) 1123–1184 (Lippincott William and Wilkins, 2001).
Andrei, G. et al. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J. Virol. 86, 2641–2652 (2012).
McGuigan, C. et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J. Antimicrob. Chemother. 60, 1316–1330 (2007).
Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).
Jordheim, L. P. & Dumontet, C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta 1776, 138–159 (2007).
Jordheim, L. P., Seve, P., Tredan, O. & Dumontet, C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12, 693–702 (2011).
Marechal, R. et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143, 664–674 (2012).
Spratlin, J. et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10, 6956–6961 (2004).
Yue, L. et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13, 29–38 (2003).
Ciccolini, J., Mercier, C., Dahan, L. & André, N. Integrating pharmacogenetics into gemcitabine dosing — time for a change? Nature Rev. Clin. Oncol. 8, 439–444 (2011). This article assesses cytidine deaminase activity in patients receiving gemcitabine.
Ciccolini, J. et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28, 160–165 (2010).
Rosell, R. et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. 10, 4215s–4219s (2004).
Marechal, R. et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15, 2913–2919 (2009).
Geutjes, E. J., Tian, S., Roepman, P. & Bernards, R. Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res. Treat. 131, 809–818 (2012).
Marechal, R. et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 116, 5200–5206 (2010).
Galmarini, C. M. et al. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98, 1922–1926 (2001).
Suzuki, K. et al. Clinical significance of high-Km 5′-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. Leuk. Res. 31, 1343–1349 (2007).
Robins, M. J. et al. Improved syntheses of 5′-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor efficacy of gemcitabine. J. Med. Chem. 53, 6040–6053 (2010).
Tang, M. W., Liu, T. F. & Shafer, R. W. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology 55, 98–101 (2012).
Tang, M. W. & Shafer, R. W. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72, e1–e25 (2012).
Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593–1608 (2009).
Bushman, F. D. et al. Massively parallel pyrosequencing in HIV research. AIDS 22, 1411–1415 (2008).
Newman, R. M. et al. Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J Infect. Dis. 6 Nov 2012 (doi:10.1093/infdis/jis679).
Solmone, M. et al. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 83, 1718–1726 (2009).
Ford, L. T. & Berg, J. D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J. Clin. Pathol. 63, 288–295 (2010).
Adam de Beaumais, T. & Jacqz-Aigrain, E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol. 68, 1233–1242 (2012).
Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137 (2006).
Kantarjian, H. et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 13, 1096–1104 (2012).
Krett, N. L. et al. 8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol. Cancer Ther. 3, 1411–1420 (2004).
Gandhi, V. et al. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res. 61, 5474–5479 (2001). This study shows the multiple and uncommon mechanisms of action of 8-chloro-adenosine; this compound acts as an analogue of ATP and is not incorporated into DNA.
Frey, J. A. & Gandhi, V. 8-amino-adenosine inhibits multiple mechanisms of transcription. Mol. Cancer Ther. 9, 236–245 (2010).
Stellrecht, C. M., Ayres, M., Arya, R. & Gandhi, V. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res. Treat. 121, 355–364 (2010).
Stellrecht, C. M., Phillip, C. J., Cervantes-Gomez, F. & Gandhi, V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 67, 9913–9920 (2007).
Yang, S. Y. et al. Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells. Biochem. Pharmacol. 77, 433–443 (2009).
Gu, Y. Y. et al. 8-chloro-adenosine inhibits growth at least partly by interfering with actin polymerization in cultured human lung cancer cells. Biochem. Pharmacol. 72, 541–550 (2006).
Choi, W. J. et al. Fluorocyclopentenyl-cytosine with broad spectrum and potent antitumor activity. J. Med. Chem. 55, 4521–4525 (2012).
Peters, G. J. et al. Metabolism and mechanism of action of fluorocyclopentenylcytosine (RX-3117). in: 103rd Annual Meeting of the American Association for Cancer Research (Chicago, Illinois, USA; 2012).
Tiwari, K. N. et al. Synthesis of 4′-thio-beta-D-arabinofuranosylcytosine (4′-thio-ara-C) and comparison of its anticancer activity with that of ara-C. Nucleosides Nucleotides Nucleic Acids 19, 329–340 (2000).
Lee, C. P. et al. A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. Clin. Cancer Res. 12, 2841–2848 (2006).
Waud, W. R., Gilbert, K. S., Shepherd, R. V., Montgomery, J. A. & Secrist, J. A. Preclinical antitumor activity of 4′-thio-beta-D-arabinofuranosylcytosine (4′-thio-ara-C). Cancer Chemother. Pharmacol. 51, 422–426 (2003).
Someya, H., Waud, W. R. & Parker, W. B. Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the anti-solid tumor activity of 4′-thio-arabinofuranosylcytosine. Cancer Chemother. Pharmacol. 57, 772–780 (2006).
Stuyver, L. J. et al. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine. Antimicrob. Agents Chemother. 48, 651–654 (2004). This paper reports the importance of the fluoro group at the 2′ position of cytidine for improved antiviral activity and specificity, as viral polymerases seem to be more tolerant towards the incorporation of such a compound.
Clark, J. L. et al. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48, 5504–5508 (2005).
Pierra, C. et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J. Med. Chem. 49, 6614–6620 (2006). This study highlights the discovery of valopicitabine, which was the first nucleoside analogue to be evaluated for the treatment of patients with HCV infection.
O'Brien, C. et al. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, versus retreatment with peg-interferon plus ribavirin (pegifn/RBV) in hepatitis C patients with previous non-response to pegIFN/RBV: first interim results. Hepatology 42, 234A (2005).
Pockros, P. J. et al. JUMP-C: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 28 Jan 2013 (doi:10.1002/hep.26275).
Wedemeyer, H. et al. PROPEL: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 24 Jan 2013 (doi:10.1002/hep.26274).
Le Pogam, S. et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis. 202, 1510–1519 (2010).
Reddy, R. et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46, 862A–863A (2007).
Chu, T. W. et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 142, 790–795 (2012).
Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467–1475 (2010). This is one of the first reports to describe the combinational use of a nucleoside analogue in an interferon-free regimen in patients with HCV infection.
DeJesus, E. et al. Elvucitabine versus lamivudine with tenofovir and efavirenz in ART-naïve HIV-1-infected patients: 96-week final results. in: 17th Conference on Retroviruses and Opportunistic Infections [online], (San Francisco, California, USA; 2010).
Bethell, R. C., Lie, Y. S. & Parkin, N. T. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir. Chem. Chemother. 16, 295–302 (2005).
Gu, Z. et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50, 625–631 (2006).
Cahn, P. & Wainberg, M. A. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. J. Antimicrob. Chemother. 65, 213–217 (2010).
Nitanda, T. et al. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob. Agents Chemother. 49, 3355–3360 (2005).
Wang, X., Tanaka, H., Baba, M. & Cheng, Y. C. Retention of metabolites of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells. Antimicrob. Agents Chemother. 53, 3317–3324 (2009).
De Clercq, E. Highlights in antiviral drug research: antivirals at the horizon. Med. Res. Rev. 2 May 2012 (10.1002/med.21256).
Price, N. B. & Prichard, M. N. Progress in the development of new therapies for herpesvirus infections. Curr. Opin. Virol. 1, 548–554 (2011). This review presents new therapies for herpesvirus infection.
Kern, E. R. et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48, 4745–4753 (2004).
Chou, S. & Bowlin, T. L. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Chemother. 55, 382–384 (2011).
Secrist, J. A., Tiwari, K. N., Riordan, J. M. & Montgomery, J. A. Synthesis and biological activity of 2′-deoxy-4′-thio pyrimidine nucleosides. J. Med. Chem. 34, 2361–2366 (1991).
Kumar, S. et al. DNA containing 4′-thio-2′-deoxycytidine inhibits methylation by HhaI methyltransferase. Nucleic Acids Res. 25, 2773–2783 (1997).
Thottassery, J. V., Tiwari, K., Westbrook, L., Secrist, J. A. & Parker, W. B. Novel 2′-deoxycytidine analogs as DNA demethylation agents. Abstract 2537 in: 102nd Annual Meeting of the American Association for Cancer Research (Orlando, Florida, USA; 2011).
Marquez, V. E. et al. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann. NY Acad. Sci. 1058, 246–254 (2005).
Cheng, J. C. et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst. 95, 399–409 (2003).
Wagner, C. R., Iyer, V. V. & McIntee, E. J. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 20, 417–451 (2000).
Rosowsky, A., Kim, S. H., Ross, J. & Wick, M. M. Lipophilic 5′-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2′-anhydro-3′-O-acyl derivatives as potential prodrugs. J. Med. Chem. 25, 171–178 (1982).
Jordheim, L. P. et al. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin. Cancer Res. 10, 5614–5621 (2004).
Hantz, O. et al. The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. Antiviral Res. 40, 179–187 (1999).
Meier, C. & Balzarini, J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antiviral Res. 71, 282–292 (2006).
Bontemps, F. et al. Study of the efficacy of a pronucleotide of 2-chloro-2′-deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells. Nucleosides Nucleotides Nucleic Acids 25, 997–1000 (2006).
Erion, M. D. et al. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126, 5154–5163 (2004). This study reports the feasibility of the 'HepDirect' approach with several nucleosides.
Erion, M. D. et al. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312, 554–560 (2005).
Reddy, K. R. et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J. Med. Chem. 51, 666–676 (2008).
McGuigan, C. et al. A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine. J. Clin. Oncol. Abstr. S29, 13540 (2011).
Vail, D. M. et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin. Cancer Res. 15, 3503–3510 (2009).
Ben-Kasus, T., Ben-Zvi, Z., Marquez, V. E., Kelley, J. A. & Agbaria, R. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem. Pharmacol. 70, 121–133 (2005).
Yoo, C. B. et al. Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2′-deoxyzebularine. J. Med. Chem. 51, 7593–7601 (2008).
Lam, A. M. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56, 3359–3368 (2012).
Lalezari, J. et al. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J. Hepatol. 54, S28 (2011).
Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013).
Sulkowski, M. S. et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. in: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (Boston, Massachusetts, USA; 2012).
Sulkowski, M. et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/− ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. J. Hepatol. 56, S560 (2012). This was one of the first reports to describe the combinational use of a nucleoside analogue in an interferon-free regimen in patients with HCV infection.
Cretton-Scott, E. et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. Hepatol. 48, S220 (2008).
Lalezari, J. et al. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology 50, 11A–12A (2009).
McCarville, J. F. et al. No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1-infected HCV subjects. J. Hepatol. 54, S488–S489 (2011).
Chapman, H. et al. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleosides Nucleotides Nucleic Acids 20, 621–628 (2001).
Babusis, D., Phan, T. K., Lee, W. A., Watkins, W. J. & Ray, A. S. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm (2012).
Lee, W. A. et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 49, 1898–1906 (2005).
Ruane, P. et al. GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients. Abstract 103 in: 19th Conference on Retroviruses and Opporunistic Infections [online], (Seattle, Washington, USA; 2012).
Uckun, F. M., Pendergrass, S., Venkatachalam, T. K., Qazi, S. & Richman, D. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob. Agents Chemother. 46, 3613–3616 (2002). This paper highlights the discovery of a compound that is active on multidrug-resistant HIV strains.
Cahn, P. et al. Preclinical and first-in-human Phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. J. AIDS Clin. Res. 3, 138 (2012).
Uckun, F. M., Cahn, P., Qazi, S. & D'Cruz, O. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opin. Investig. Drugs 21, 489–500 (2012).
Ryu, E. K. et al. Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5′-monophosphate-l-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-l-1,2-diacylglycerols. J. Med. Chem. 25, 1322–1329 (1982).
Aoshima, M., Tsukagoshi, S., Sakurai, Y., Oh-ishi, J. I. & Ishida, T. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res. 37, 2481–2486 (1977).
Breistol, K. et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res. 59, 2944–2949 (1999).
Adema, A. D. et al. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest. New Drugs 30, 1908–1916 (2012).
Galmarini, C. M., Myhren, F. & Sandvold, M. L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br. J. Haematol. 144, 273–275 (2009).
Immordino, M. L. et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Control Release 100, 331–346 (2004).
Brusa, P., Immordino, M. L., Rocco, F. & Cattel, L. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Anticancer Res. 27, 195–199 (2007).
Chung, W. G., Sandoval, M. A., Sloat, B. R., Lansakara, P. D. & Cui, Z. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J. Control Release 157, 132–140 (2012).
Bergman, A. M. et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem. Pharmacol. 67, 503–511 (2004).
Bergman, A. M. et al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest. New Drugs 29, 456–466 (2011).
Damaraju, V. L. et al. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids 31, 236–255 (2012).
Garcia-Manteiga, J., Molina-Arcas, M., Casado, F. J., Mazo, A. & Pastor-Anglada, M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin. Cancer Res. 9, 5000–5008 (2003).
Couvreur, P. et al. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4, 247–253 (2008).
Reddy, L. H. et al. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol. Pharm. 6, 1526–1535 (2009). This study validates the in vitro feasibility of the squalenoylation approach.
Rejiba, S. et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 7, 841–849 (2011).
Sarpietro, M. G. et al. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. Int. J. Pharm. 406, 69–77 (2011).
Cosco, D. et al. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. Int. J. Nanomed. 7, 2535–2546 (2012).
Maksimenko, A. et al. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy. Cancer Lett. (2012).
Kiew, L. V., Cheong, S. K., Sidik, K. & Chung, L. Y. Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation. Int. J. Pharm. 391, 212–220 (2012).
Pasut, G. et al. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control Release 127, 239–248 (2008).
El-Mabhouh, A. A. & Mercer, J. R. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases. Eur. J. Nucl. Med. Mol. Imag. 35, 1240–1248 (2008).
El-Mabhouh, A. A. et al. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases. Oncol. Res. 19, 287–295 (2011).
Guo, P. et al. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother. Pharmacol. 48, 169–176 (2001).
Strasser, S. et al. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. Differ. 74, 488–498 (2006).
Lanier, E. R. et al. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob. Agents Chemother. 54, 2901–2909 (2010).
McGuigan, C. et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J. Med. Chem. 42, 4479–4484 (1999).
Pentikis, H. S. et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob. Agents Chemother. 55, 2847–2854 (2011).
Brueckner, B. et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol. Cancer Ther. 9, 1256–1264 (2010).
Veltkamp, S. A. et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin. Cancer Res. 14, 3477–3486 (2008).
Bender, D. M. et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J. Med. Chem. 52, 6958–6961 (2009).
Pratt, S. E. et al. Human carboxylesterase 2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin. Cancer Res. 19, 1159–1168 (2013).
Koolen, S. L. et al. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin. Cancer Res. 17, 6071–6082 (2011). This is the first report of the clinical use of an orally active gemcitabine conjugate.
Hao, W. H. et al. In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation. Cancer Chemother. Pharmacol. 71, 379–388 (2013).
Maloisel, F. et al. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia 16, 573–580 (2002).
Mollee, P. et al. Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Ann. Oncol. 15, 1810–1815 (2004).
Horikoshi, A., Takei, K., Hosokawa, Y. & Sawada, S. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. Int. J. Hematol. 87, 118–125 (2008).
Gokbuget, N. et al. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 96, 238–244 (2011).
Calvagno, M. G. et al. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr. Drug Deliv. 4, 89–101 (2007).
Arias, J. L., Reddy, L. H. & Couvreur, P. Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system. Biomacromolecules 12, 97–104 (2011).
Celia, C., Cosco, D., Paolino, D. & Fresta, M. Gemcitabine-loaded innovative nanocarriers versus GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin. Drug Deliv. 8, 1609–1629 (2011).
Feldman, E. J. et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29, 979–985 (2011).
Zhao, X., Wu, J., Muthusamy, N., Byrd, J. C. & Lee, R. J. Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment. J. Pharm. Sci. 97, 1508–1518 (2008).
Rose, W. C., Crosswell, A. R., Bronson, J. J. & Martin, J. C. In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues. J. Natl Cancer Inst. 82, 510–512 (1990).
Holy, A. et al. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res. 13, 295–311 (1990).
Tsai, C. Y. et al. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin. Cancer Res. 15, 3760–3769 (2009).
Suzuki, N., Nakagawa, F., Nukatsuka, M. & Fukushima, M. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp. Ther. Med. 2, 393–397 (2011).
Temmink, O. H. et al. Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. Mol. Cancer Ther. 9, 1047–1057 (2010).
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M. & Kitazato, K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int. J. Mol. Med. 13, 545–549 (2004).
Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13, 993–1001 (2012).
Clouser, C. L. et al. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg. Med. Chem. Lett. 22, 6642–6646 (2012).
Clouser, C. L. et al. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS ONE 6, e15840 (2011). This study reports on the antiviral activity of the cytotoxic nucleoside analogue gemcitabine.
Elwell, L. P. et al. Antibacterial activity and mechanism of action of 3′-azido-3′-deoxythymidine (BW A509U). Antimicrob. Agents Chemother. 31, 274–280 (1987).
Lewin, C. S., Allen, R. A. & Amyes, S. G. Mechanisms of zidovudine resistance in bacteria. J. Med. Microbiol. 33, 235–238 (1990).
Doleans-Jordheim, A. et al. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur. J. Clin. Microbiol. Infect. Dis. 30, 1249–1256 (2011).
Jordheim, L. P. et al. Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. Int. J. Antimicrob. Agents 39, 444–447 (2012).
Groves, A. M., Win, T., Haim, S. B. & Ell, P. J. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 8, 822–830 (2007).
Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).
Tatlisumak, T. et al. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 29, 1952–1958 (1998).
Sharma, N. K., Mahadevan, N. & Balakumar, P. Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors. Cardiovasc. Toxicol. 13, 22–32 (2013).
Richman, D. D. HIV chemotherapy. Nature 410, 995–1001 (2001).
Leyssen, P., De Clercq, E. & Neyts, J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78, 9–25 (2008).
Broder, C. C. Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr. Opin. Virol. 2, 176–187 (2012).
Chevaliez, S., Brillet, R., Lazaro, E., Hezode, C. & Pawlotsky, J. M. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81, 7732–7741 (2007).
Vignuzzi, M., Stone, J. K. & Andino, R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107, 173–181 (2005).
Ewald, B., Sampath, D. & Plunkett, W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27, 6522–6537 (2008).
McGinn, C. J., Shewach, D. S. & Lawrence, T. S. Radiosensitizing nucleosides. J. Natl Cancer Inst. 88, 1193–1203 (1996).
Kantarjian, H. et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J. Clin. Oncol. 28, 285–291 (2010). This study shows the clinical safety of the new oral nucleoside analogue sapacitabine.
Gilbert, J., Carducci, M. A., Baker, S. D., Dees, E. C. & Donehower, R. A. Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Invest. New Drugs 24, 499–508 (2006).
Delaunoit, T. et al. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. Invest. New Drugs 24, 327–333 (2006).
Radhakrishnan, S. K. & Gartel, A. L. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res. 66, 3264–3270 (2006).
Nekhai, S. et al. A novel anticancer agent ARC antagonizes HIV-1 and HCV. Oncogene 26, 3899–3903 (2007).
Bhat, U. G. & Gartel, A. L. Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells. Leukemia 24, 851–855 (2010).
Le Guerhier, F. et al. Antiviral activity of beta-l-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob. Agents Chemother. 45, 1065–1077 (2001).
Lin, T. S. et al. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-beta-l-cytidine (beta-l-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-beta-l-5-fluorocytidine (beta-l-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39, 1757–1759 (1996).
Le Guerhier, F. et al. Characterization of the antiviral effect of 2′,3′-dideoxy-2′, 3′-didehydro-beta-l-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 44, 111–122 (2000).
Cahn, P. et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. Aids 20, 1261–1268 (2006).
Wainberg, M. A., Cahn, P., Bethell, R. C., Sawyer, J. & Cox, S. Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. Antivir. Chem. Chemother. 18, 61–70 (2007).
Gouy, M. H. et al. Special feature of mixed phosphotriester derivatives of cytarabine. Bioorg. Med. Chem. 17, 6340–6347 (2009).
Tobias, S. C. & Borch, R. F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol. Pharm. 1, 112–116 (2004).
Rodriguez-Torres, M. et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 58, 663–668 (2012).
Lawitz, E. et al. High rapid virologic response (RVR) with PSI-7977 qd plus PEG-IFN/RBV in a 28-day phase 2a trial. Hepatology 52, 706A (2010). This is a description of the antiviral activity of sofosbuvir, which is probably the first 'pure chain terminator' nucleotide analogue to be used against HCV.
Vernachio, J. H. et al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob. Agents Chemother. 55, 1843–1851 (2011).
O'Brien, S. et al. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br. J. Haematol. 158, 581–588 (2012).
Giles, F. et al. Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leuk. Res. 36, e71–e73 (2012). This is a report on the clinical activity of the elaidic acid derivative of cytarabine.
Bildstein, L. et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J. Control Release 147, 163–170 (2010).
Chuang, J. C. et al. S110, a 5-aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 9, 1443–1450 (2010).
Yoo, C. B. et al. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67, 6400–6408 (2007).
Painter, G. R. et al. Evaluation of hexadecyloxypropyl-9-R−[2-(phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother. 51, 3505–3509 (2007).
Painter, W. et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob. Agents Chemother. 56, 2726–2734 (2012).
The authors acknowledge the support of the Association pour la Recherche sur le Cancer (ARC) and the Ligue contre le Cancer. L.P.J. acknowledges the Olav Raagholt and Gerd Meidel Raagholt Foundation for Research (Olav Raagholt og Gerd Meidel Raagholts stiftelse for medisinsk forskning).
F.Z. has received consulting/speaking fees from Gilead, Bristol-Myers Squibb and Janssen Cilag.
F.Z. and D.D. have received research grants from Roche.
C.D. and L.P.J. have received research grants from Clavis Pharma.
Currently approved nucleos(t)ide analogues and indications (PDF 113 kb)
Main enzymatic activities targeted by nucleos(t)ide analogues for different chronic viruses (PDF 118 kb)
Mutations in different viral polymerases conferring resistance to nucleos(t)ide analogues (PDF 138 kb)
Associations between genetic variants and response to nucleoside analogue therapy in cancer patients (PDF 147 kb)
- Ribonucleotide reductase
A complex intracellular enzyme that converts ribonucleoside diphosphates into deoxyribonucleoside diphosphates, and is targeted by anticancer agents such as gemcitabine.
A nitrogen-containing heterocyclic compound that can be grouped into purines (adenine and guanine) and pyrimidines (cytosine, thymine and uracil).
- Dose adaptation
Determination of the dose that should be administered to a patient based on predicted or observed toxicity.
- Demethylating agents
Compounds that modify the methylation status of regulatory sequences in DNA, thereby modifying the levels of expression of the corresponding gene.
- Nucleoside transporters
Membrane pumps that allow the uptake and/or the efflux of nucleosides by cells.
- Chain elongation
The increase in length of DNA or RNA strands during replication or transcription.
- Phenotypic assays
Assays in which biological function or cell response is measured as an index of drug action.
Phosphorylated nucleosides in which the phosphate is linked to a protective group to increase diffusion of the nucleoside across the cell membrane.
- Nucleophilic attack
A chemical reaction in which a negatively charged entity forms a bond with a positively charged atom.
Compounds that are administered as inactive pharmacological entities that are then metabolized in vivo into an active compound.
- Sustained viral response
The absence of detectable virus in the blood for up to 6 months after treatment.
- First-pass hepatic metabolism
The uptake and metabolism of an orally administered drug by enzymes in the liver, which reduces the concentration of the drug in the systemic circulation.
- Phase 0 trial
A first-in-human clinical trial that is carried out to determine the pharmacodynamic and pharmacokinetic properties of a drug.
- Drug repositioning
A strategy in which drugs that were initially developed in a given indication are subsequently applied to a novel indication.
About this article
Cite this article
Jordheim, L., Durantel, D., Zoulim, F. et al. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 12, 447–464 (2013). https://doi.org/10.1038/nrd4010
DFT, Monte Carlo and molecular dynamics simulations for the prediction of corrosion inhibition efficiency of novel pyrazolylnucleosides on Cu(111) surface in acidic media
Scientific Reports (2021)
Medicinal Chemistry Research (2021)
Synthesis of novel selenotetrazole purine derivatives and their potential chemotherapeutic activities
Medicinal Chemistry Research (2021)
Medicinal Chemistry Research (2021)
Significant Inhibition of Porcine Epidemic Diarrhea Virus In Vitro by Remdesivir, Its Parent Nucleoside and β-d-N4-hydroxycytidine
Virologica Sinica (2021)